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Background: Early and progressive disabling visual impairment is a core feature for the 
diagnosis of posterior cortical atrophy (PCA). However, some individuals that fulfil criteria 
over time might initially present with an onset of prominent posterior dysfunction other than 
visuoperceptual. Methods: The clinical profile of five patients with a predominantly ‘non-
visual’ posterior presentation (PCA2) was investigated and compared with sixteen individuals 
with visually predominant PCA (PCA1) and eighteen with typical amnestic Alzheimer 
disease (tAD). Results: PCA2 patients showed significantly better performance than PCA1 in 
one visuospatial task and were free of Balint’s syndrome and visual agnosia.  Compared to 
tAD, PCA2 showed trends towards significantly lower performance in visuoperceptual tasks, 
more severe apraxia and more symptoms of Gerstmann’s syndrome. Conclusions: Our 
sample of PCA2 patients did not present with clinically prominent visual symptoms but did 
show  visual dysfunction on formal neuropsychological assessment (less pronounced than in 
PCA1 but more than in tAD) in addition to other posterior deficits. Broadening the definition 
of PCA to encompass individuals presenting with prominent ‘non-visual’ posterior 
dysfunction should be potentially considered in clinical and research contexts.  
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1. Introduction 
Posterior cortical atrophy (PCA) [1] is characterised by early, prominent and progressive 
impairment of visual function and other posterior cortical functions in the context of 
relatively preserved memory and insight and a pattern of atrophy involving the parietal, 
occipital and posterior temporal lobes [2, 3, 4, 1, 5]. The most common pathology in PCA is 
Alzheimer’s disease, and it is now recognized in Alzheimer’s disease diagnostic and research 
criteria as the most common atypical Alzheimer’s disease phenotype [6, 7]. In a small 
number of cases the syndrome can also be caused by Lewy body disease and corticobasal 
degeneration [1, 8, 9]. 
PCA is a relatively heterogeneous syndrome, [10]. The most commonly described PCA 
presentation is parieto-occipital [1, 11, 12] and roughly comparable to what it has been called 
‘biparietal AD’ [13, 14, 15, 16]. The new IWG criteria [7] contrast this biparietal subtype of 
PCA, characterised primarily by visuospatial deficits (e.g simultagnosia) with an occipito-
temporal subtype, characterised by visuoperceptual deficits (e.g. failing to recognise objects). 
Both variants share in common the presence of early visual impairment as a core feature for 
the diagnosis. 
Some patients with posterior presentations of AD may develop posterior features others than 
vision like apraxia, agraphia, acalculia and difficulties in navigation. Although visual 
symptoms may develop over time, the initial presentation in these individuals is dominated 
by other posterior features [17, 16]. Strictly speaking, some of these patients do not meet 
criteria for PCA due to the lack of prominent visual complaints (Mendez et al., 2012 [17] 
criteria require ‘presentation with visual complaints with intact primary visual functions’; 
while Tang-Wai et al., 2004 [1] criteria require ‘presentation of visual complaints in the 
absence of significant primary ocular disease explaining the symptoms’). However, 
comprehensive neuropsychological testing of patients presenting with posterior non-visual 
complaints may uncovers evidence of impairments in visual cognition. These individuals are 
the focus of the current study. 
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Here we compare the clinical features of a sample of patients with a ‘non-visual’ posterior 
presentation AD (PCA2) with a group of patients with visually-predominant PCA (PCA1) 
and a group of individuals with typical amnestic AD (tAD). We hypothesized that detailed 
investigation of the PCA2 patients would yield evidence of cortical visual impairment 
sufficient to justify their potential classification as PCA, whilst also exhibiting groupwise 
differences in cognitive profile compared with patients with PCA1 and tAD.  
2. Methods 
2.1. Participants 
Participants were recruited at the Memory Disorders Unit of the Hospital Virgen del Rocio 
and consisted of 16 patients diagnosed with PCA (classical visually-predominant PCA, 
labelled PCA1), 18 typical amnestic AD (tAD) and 5 with a predominantly ‘non-visual’ 
posterior presentation AD (labelled PCA2). Inclusion criteria required that AD patients met 
diagnosis criteria for probable AD [6], and PCA patients met Tang-Wai et al. criteria for PCA 
[1]. The 5 patients with PCA2 presented with a history of insidious onset and progression of 
bilateral apraxia/constructive apraxia/dysgraphia, dyscalculia, anomia and navigation 
difficulties to variable degrees (see Figure 1 for a case example and Supplementary Material 
for a brief description of the five participants), which were confirmed during the clinical 
interview and neurological examination. Most of them reported environmental disorientation, 
which might be interpreted as a visuospatial function, but none of the cases had this as the 
most prominent symptom or main cause of restriction of independence in daily activities. 
According to the current diagnostic criteria for AD [6], these PCA2 patients might be 
classified as a non-amnestic presentation AD. Within the non-amnestic forms, given their 
navigation difficulties and constructive apraxia, they might be classified as the visuospatial 
presentation of AD. However, they do not meet the current criteria for PCA, as they do not 
present with visual complaints, which is a core feature for the diagnosis. For example, a 
typical case study reported by Crutch [5] shows a 62-year-old woman “Her first symptom 
was difficulty seeing when driving at night. In the following years she frequently dented her 
car when parking, tended to bump into doors … and had trouble locating items even when 
they were directly in front of her”. Our case example in Figure 1 shows the clinical picture of 
one of our patients in the PCA2 group and represents an example of how our five PCA2 
participants differ from the visually predominant (PCA1) presentation. 
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Participants were diagnosed and reviewed once or twice per year enabling the authors to 
gather further supportive evidence regarding the diagnosis over time. The study was 
approved by the Virgen del Rocío Hospital Ethics Committee and conducted according to the 
Principles of Helsinki Declaration.  
2.2. Cognitive testing 
A comprehensive cognitive assessment was performed with all participants by the same 
neuropsychologist (ASG) including evaluation of memory, executive function, reading, 
writing, praxis, object and space perception and elements of Balint’s and Gerstmann’s 
syndromes. The formal testing consisted of nineteen tasks including: Mini Mental State 
Examination (MMSE) [18], attention, executive functions and working memory [19], 
episodic memory [20] and object naming [21], for which a verbal description of each item 
was provided to avoid bias due to visual impairment. The posterior function assessment 
included tests of spoken and written word comprehension, copy and dictation, upper limb 
ideomotor and ideational praxis [19], and early visual, visuoperceptual and visuospatial 
processing (Visual Object and Space Perception [VOSP] battery) [22]. The assessment of 
Balint´s and Gerstmann´s syndromes and other posterior features involved tests of 
simultanagnosia (description of the Cookie Theft picture) [21], ocular apraxia (following a 
moving target with the eyes) [23], optic ataxia (reach a moving target with the right hand in 
the four visual quadrants) [24], acalculia (subtraction, addition, writing and reading 
numbers), agraphia (as above), left-right disorientation (pointing to 10 body parts on 
own/examiner´s body) [19], finger agnosia (finger identification to visual and verbal 
command), alexia (reading single words and short sentences), constructional praxis (MMSE 
pentagons and cube copying), and patient and carer ratings of spatial disorientation and 
dressing apraxia. 
2.3. Neuroimaging data 
All patients underwent neuroimaging assessments (CT or MRI) but only 30 MRIs were 
available for visual assessment. MRI were evaluated using the Scheltens scale for medial 
temporal lobe atrophy (MTA; range 0-4) [25] and Koedam scale for posterior atrophy (PA; 
range 0-3) [26]. The rater was blinded to the clinical diagnosis and clinical data and the MTA 
and PA were rated once. 
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2.4. Genetic analysis 
DNA was extracted from blood samples collected from patients and APOE genotype was 
determined using the polymerase chain reaction (PCR) amplification method modified by 
Wenham [27]. 
2.5. Statistical analysis 
Pairwise comparisons were performed using unmatched t-tests or Mann-Whitney U tests for 
quantitative variables and Fisher´s exact or Chi square tests for qualitative variables.  
3. Results 
3.1. Demographics and cognitive data 
Demographic and clinical characteristics of the sample are summarized in Table 1. There 
were no significant differences between subgroups in age, disease duration or MMSE. 
Performance on formal neuropsychological tests and pairwise comparisons between the 
PCA1, PCA2 and tAD groups are shown in Table 2 and Table 3. No differences were found 
between PCA2 and the other two groups in attention, executive function, working memory, 
verbal memory and language. Compared with patients with visually-predominant PCA 
(PCA1), PCA2 patients were significantly less impaired on VOSP Number location 
(visuospatial processing) (p = .03). However there was no evidence of PCA2 patients 
performing significantly worse than PCA1 patients on any of the cognitive tasks 
administered. Compared with tAD patients, PCA2 patients demonstrated a significantly 
greater impairment in praxis, as measured by symbolic, object use ideomotor praxis and 
ideational praxis subtests (p = .03, p = 0.005 and  p = .006, respectively). These significant 
differences in praxis performance were not observed between PCA1 and PCA2. Table 3 also 
displays the number of patients performing under percentile 5 in the visuospatial/perceptual 
tests. All the patients in PCA1 and PCA2 groups failed at least one test of visual function, 
while this proportion was half in the tAD group. 
The frequency and pairwise comparisons of posterior symptoms in each group are shown in 
Table 4. With regard to the features of Gerstmann´s syndrome (typically associated with left 
parietal lesions), PCA2 patients showed the highest frequency of finger agnosia (20%) and 
the second highest behind the PCA1 group of acalculia, agraphia, left-right disorientation and 
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alexia. By contrast, PCA1 patients frequently showed features of Balint´s syndrome 
(typically associated with bilateral occipitoparietal lesions), namely simultanagnosia (50%), 
ocular apraxia (31%) and optic ataxia (6%) whilst these features were not detected in any of 
the patients with PCA2. None of the PCA2 participants showed visual agnosia whilst it was 
present in 33% of the PCA1 group. 
3.2. Neuroimaging 
MRI scans were available for 30 of the 39 individuals that constituted the sample. No 
significant differences were found in MTA or PA across groups (see Table 1).  
3.3. Genetics 
APOE genotype was available for 34 individuals. Within tAD group, 21% of the patients 
were ɛ4 homozygotes, whereas none of the PCA1 or PCA2 patients had more than one ɛ4 
allele (see Table 1). 
4. Discussion 
In this study, 5 individuals with a predominantly ‘non-visual’ posterior cortical impairment 
(PCA2) were compared with 16 individuals with visually-predominant PCA (PCA1) and 18 
typical amnestic AD (tAD). Patients with PCA2 showed significantly worse performances in 
praxis and a higher proportion of Gerstmann’s syndrome symptoms than the tAD group. 
Consistent with their predominantly ‘non-visual’ presentation, none of the PCA2 patients 
assessed showed any of the symptoms of Balint’s syndrome or visual agnosia, and they were 
significantly better than PCA1 patients on one of the tests of visuospatial processing (VOSP 
Number location). However, despite the absence of significant visual impairment at 
presentation, 100% of the patients in the PCA2 group failed at least 1 test of visual 
processing. We also found a high degree of overlap between PCA2 and the two other 
syndromes, as demonstrated by the absence of inter-group differences in attention, working 
memory, verbal memory and language.  
In the present study patients with PCA2 showed considerable variability in the praxis scores. 
This variability is mainly driven by participant P23. Interestingly, this is the highest educated 
individual in the PCA2 sample (see Supplementary Material) and although there are no 
differences between P23 and the rest of PCA2 in terms of reported disease duration, P23 
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performs better in most of the cognitive tasks. His high education level might have a 
protective effect that explains these differences. It is also possible that because his occupation 
was highly demanding in terms of visuospatial and calculation skills he had noticed the 
symptoms earlier than the rest of the participants (who were exposed to less demanding 
environments) and therefore having been seen in clinic at an earlier stage. Regarding the 
pairwise comparison of cognitive scores between PCA2 and PCA1, significant differences 
were found only in one test of visuospatial processing. One possibility to explain why no 
more significant differences were found between groups is that the tests used might lack 
sensitivity to capture degrees of impairment (i.e. not graded in difficulty). Additionally, the 
size of the PCA2 sample was small, and the PCA samples consisted of individuals at different 
stages of the disease (range of MMSE between 9 and 23) with the consequent variability.  
Similar clinical presentations to those reported for the PCA2 have been described previously 
in the literature. For instance, Green et al. [13] reports a patient with slowly progressive 
apraxia, alien hand syndrome and AD pathology. Ross et al. [28] described four patients with 
a history of early visuospatial problems, agraphia of a predominantly peripheral type and 
difficulty with bimanual tasks. Neuroimaging in this patient disclosed bilateral parietal lobe 
atrophy and authors discussed the existence of two main clinical syndromes with features 
reflecting involvement of the occipitotemporal and biparietal cortical areas respectively. 
Aharon et al. [3] described 2 patients presenting with symptoms suggestive of PCA and 2 
more presenting with apraxia as the initial manifestation and also impairment of functions 
related to the dominant parietal lobe. In this study the authors suggested that PCA represents 
two clinically related behavioural phenotypes, one characterised by visuospatial disturbances 
and the other one by apraxia. Four years later Galton et al. [15] presented two patients with 
progressive biparietal syndrome and pathologically proven AD. Both individuals presented 
with moderate memory impairment but the dominant symptoms were apraxia, dysgraphia and 
visual disorientation in one case and simultanagnosia in the other. Mendez et al. [17] also 
described, in a retrospective series, a group of patients with prominent limb apraxia who met 
diagnostic criteria for AD. Characteristically these patients presented with dysgraphia and 
limb apraxia, and acalculia was a common feature. Marques et al. [16] also reported a case of 
a young patient with progressive limb apraxia and choreiform movements, severe impairment 
in visuoconstructive abilities, dyscalculia, β-amyloid reduction and tau increase in CSF. The 
studies above show historical evidence of patients with probable or definite AD presenting 
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with early and prominent involvement of parietal functions and a lesser degree of 
visuoperceptual impairment. In this context, a possible explanation to the milder visual 
impairment showed by our PCA2 group might be that the involvement of the occipital lobe 
occurs later in the course of the disease compared to PCA1. Although damage to the parietal 
lobe is sufficient to produce visuospatial impairment (e.g. poor performance on judgment of 
line orientation tasks), other visual symptoms usually result from lesions extending to the 
occipital regions (e.g. simultanagnosia). It is therefore possible that late involvement of these 
regions might explain the later decline of these functions in the PCA2 group. 
For all groups in our sample, the mean MTA ratings were indicative of mild atrophy and the 
mean PA ratings indicated moderate atrophy. This pattern has been reported in patients with 
young onset AD [29] and therefore expected to be found in our amnestic AD sample, for 
which the mean age was 60 years. However no differences were found across groups. PCA1 
and PCA2 tend to be ɛ4 negative [30, 31, 32]. In our sample, ɛ4/ɛ4 homozygocity was present 
only in individuals with tAD, similar to previous studies [31, 32]. However, it is notable that 
the percentage of individuals with at least one ɛ4 allele was as high in the PCA1 and PCA2 as 
in the tAD. This may be due to the small size of the PCA groups, not accurately representing 
the actual distribution of ɛ4 in this population. It might also be that our individuals with 
PCA2 may represent a point in the early-onset AD phenotypic spectrum on the boundaries 
between amnestic (ɛ4+) and atypical non-amnestic presentations (ɛ4-), as it has been reported 
that different clinical presentations of AD reflect variability along a neuroanatomical 
continuum [33, 29]. 
This study is not without limitations. First, the small size of the PCA2 group reduces the 
power of the analysis. Second, differences in both cognitive and anatomical profiles are 
easier to capture in early stages of the disease but some patients were at moderate stages at 
the time of assessment, which might have hindered the detection of significant discrepancies 
both in the cognitive and radiological profile. Lastly, the lack of pathological studies in the 
present sample makes impossible to exclude the presence of non-AD pathologies contributing 
to the clinical picture.  
In summary, our ‘non-visual’ PCA sample represents a minority of patients with 
predominantly posterior AD that do not fulfil the current clinical diagnostic criteria for PCA 
given the absence of prominent visual deficits at the onset of the disease. Impairments of 
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visuoperceptual and visuospatial processing were less pronounced in ‘non-visual’ PCA than 
in visual PCA; however a certain degree of visual dysfunction was confirmed on formal 
neuropsychological examination along with other markedly impaired posterior functions.  
The umbrella of the term PCA should allow flexibility to potentially consider patients with 
predominant posterior dysfunction without prominent visual symptoms in clinical and 
research contexts. 
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Table 1.   Demographics, clinical characteristics, visual ratings of medial temporal lobe and posterior atrophy and APOE 
genotypes of all patients 
    
Pairwise comparison† 
Patient group tAD PCA1 PCA2 PCA2 vs PCA1 PCA2 vs tAD 
N 18 16 5 
  Symptom onset Memory Vision Posterior non-vision   
Gender (%female) 11 (61%) 9 (56%) 3 (60%) 0.64* 1.00* 
Disease duration 4.4 ±2.5 4.2±2.9 3.6±1.3 0.86 0.70 
Age at assessment 60.1±4.8 63.1±5.3 62±5.9 0.70‡ 0.54‡ 
MMSE 
 
18±4.8      
(11-28) 
 
15±3.5   
(10-21)  
 
18±5.8       
 (9-23) 
0.25‡ 0.78‡ 
MTA§ 
 
0.8±0.9 
1 (0-3) 
 
1.1±0.9 
1 (0-4) 
 
1.5±1.0 
1 (0-3) 
0.74 0.20 
PA§ 
 
2.0±1.0 
2 (0.3) 
 
2.3±0.7 
2 (1-3) 
 
2.3±0.8 
2.5 (1-3) 
0.95 0.52 
    
  APOE ɛ2/ɛ3 (%)¶ 2 (14%) 
    APOE ɛ3/ɛ3 (%) 4 (28%) 9 (60%) 2 (40%) 0.63* 0.58* 
APOE ɛ4/ɛ3 (%) 5 (35%) 6 (40%) 3 (60%) 0.59* 0.31* 
APOE ɛ4/ɛ4 (%) 3 (21%)         
Data presented as N (%), median (range) or mean (SD). Abbreviations:  MTA, medial temporal atrophy visual rating scale; 
PA, posterior atrophy visual rating scale. 
 
† Mann-Whitney U test (except indicated) 
* Fisher exact test. 
‡ Unpaired t-test. 
§ MR available for 30 individuals: 9 tAD, 16 PCA1, 5 PCA2. 
¶ APOE available for 34 individuals: 14 tAD, 15 PCA1, 5 PCA2.  
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Table 2.   Background neuropsychological data:  mean±SD and significance of pairwise comparison between groups 
       Pairwise comparison 
Patient groups tAD  PCA1  PCA2  PCA2 vs PCA1 PCA2 vs tAD 
N 18  16  5  p† p† 
Verbal Fluency         
    Phonemic 10.6±12.1  8.8±7.6  16.8±11.0  0.08
‡ 0.29 
    Semantic  8.4±4.9  5.1±3.9  3.4±3.3  0.39
‡ 0.04‡ 
Digit forward 4.0±1.2  3.3±1.1  4.2±1.0  0.16 0.76 
Digit backward 2.2±1.2  1.0±1.1  1.8±1.7  0.32 0.66 
WL immediate 9.3±7.5  6.5±6.3  10.6±7.4  0.20 0.60 
WL delayed 0.5±1.2  0.1±0.7  0.8±1.7  0.33 0.82 
Brief BNT 11.6±3.0  9.0±3.7  9.6±4.1  0.67 0.24 
Praxis         
    Imitation 6.7±2.2  3.3±3.1  4±3.7  0.71
‡ 0.08 
    Symbolic 9.8±0.4  9.3±1.7  6±5.4  0.11 0.03 
    Object use 8.5±2.9§  4.8±4.2  2±4.4  0.15 0.005 
    Ideational  
 
2§  1.6±0.8  1.3±1.0  0.34 0.006 
 
Bold means statistically significant. Italics means trends towards significance. WL: Word List (Wechsler et al., 1987); 
BNT: Boston Naming Test (Goodglass et al., 2000). 
†Mann-Whitney U test (except indicated). 
‡ unpaired t-test. 
§ n=14 
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Table 3.   Performances in VOSP subtests,  number of patients scoring under 5%ile pairwise and comparison between groups 
                          Pairwise comparison 
 
Patient groups 
 
tAD 
 
 
PCA1 
 
 
PCA2 
 
PCA2 
vs 
PCA1 
PCA2 
vs 
tAD 
N 18 
n (%) under 
5%ile 
16 
n (%) under 
5%ile 
5 
n (%) under 
5%ile 
p† p† 
 
Screening 
(Figure-ground 
discrimination) 
 
18.5±2.4 10 (45%) 13.4±6.4 10 (62%) 14.8±5.4 4 (80%) 0.70 0.06 
Incomplete    
letters 
 
12.2±6.7 11 (61%) 3.8±5.8 14 (88%) 7.0±6.9 4 (80%) 0.18 0.13‡ 
Silhouettes 12.0±6.4 6 (27%) 7.5±5.8 15 (93%) 7.6±7.9 4 (80%) 0.97‡ 0.20‡ 
Dot counting 7.2±3.6 2 (11%) 5.0±3.7 10 (62%) 6.8±4.3 2 (40%) 0.31 0.90 
Position  
discrimination 
 
14.3±5.9 8 (44%) 10.1±5.3 13 (81%) 9.8±5.1 4 (80%) 0.77‡ 0.06 
Number location 5.1±4.1 8 (44%) 1.0±1.3 16 (100%) 3.6±4.1 3 (60%) 0.03‡ 0.44 
Cube analysis 5.8±3.8 10 (45%) 1.0±1.3 16 (100%) 3.6±4.5 3 (60%) 0.32 0.27‡ 
% of patients 
failing at least 1 
visual test 
 
 
10 (55%) 
 
 
16 (100%) 
 
 
5 (100%) 
 
  
Performances expressed in mean ± SD. Bold means statistically significant. Italics means trends towards significance. 
†Mann-Whitney U test (except indicated). 
‡ unpaired t-test. 
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Table 4. Frequency of posterior symptoms and pairwise comparison in each group 
    Pairwise comparison 
Patient group tAD PCA1 PCA2 PCA2 vs PCA1 PCA2 vs tAD 
N 18 16 5 p* p* 
 
Ocular apraxia 
 
1 (5%) 
 
5 (31%) 
 
0 
 
0.21 
 
0.78 
Optic ataxia 0 1 (6%) 0 0.76 - 
Simultagnosia 1 (5%) 8 (50%) 0 0.06 0.78 
 
  
 
  
Acalculia 5 (27%) 11 (68%) 3 (60%) 0.55 0.26 
Agraphia 2 (11%) 12 (75%)  1 (20%) 0.04 0.57 
Left-Right disorientation 3 (16%)  8 (50%) 2 (40%) 0.55 0.49 
Finger agnosia 0 3 (18%) 1 (20%) 0.71 0.21 
 
  
 
  
Alexia 3 (16%) 9 (56%) 2 (40%) 0.45 0.33 
Spatial disorientation 7 (38%) 13 (81%) 1 (20%) 0.02 0.41 
Dressing apraxia 5 (27%) 9 (56%) 2 (40%) 0.45 0.49 
Constructive apraxia 12 (66%) 14 (87%) 3 (60%) 0.22 0.58 
Visual agnosia 1 (5%) 6 (33%) 0 0.14 0.78 
 
* Fisher exact test. 
Patients with PCA2 show the second highest percentage (after PCA1) of individuals showing acalculia, alexia, dressing 
apraxia and visuospatial difficulties at the assessment time. However, they do not show any of the components of Balint 
syndrome or visual agnosia.  
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Figure captions 
Figure 1. Illustrative case of a PCA2 patient. Magnetic resonance T1-weighted images 
showing pronounced atrophy of the posterior cortices (L>R) with moderate hippocampal 
involvement. R = right.   
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